Urinary Bladder, Overactive - Etiology
Research News and Information

Monday, November 23, 2009

Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.

13 Aug 2009 PURPOSE: Urinary disturbances are common in patients with Parkinson's disease and multiple system atrophy. We investigated the effectiveness and safety of botulinum toxin type A injected into the detrusor muscle in patients with Parkinson's disease ... Read more...

Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

20 Jul 2009 OBJECTIVES: To evaluate the efficacy and safety of oxybutynin transdermal system (oxybutynin-TDS) in spinal cord injury patients with neurogenic detrusor overactivity and incontinence despite use of clean intermittent catheterization (CIC). METHODS: ... Read more...

Lower urinary tract dysfunction in acute disseminated encephalomyelitis.

29 Jun 2009 BACKGROUND: Lower urinary tract dysfunction (LUTD) in multiple sclerosis has been well documented. However, its occurrence and outcome in acute disseminated encephalomyelitis (ADEM) has only been variably reported. OBJECTIVE: To evaluate LUTD in ... Read more...

Latest indexed articles for 'Urinary Bladder, Overactive - Etiology'

These are the very latest articles for this heading:

• Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. 13 Aug 2009
• How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist. 30 Jul 2009
• Editorial comment. Effect of pelvic floor interferential electrostimulation on urodynamic parameters and incontinency of children with myelomeningocele and detrusor overactivity. 30 Jul 2009
• Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. 20 Jul 2009
• Lower urinary tract dysfunction in acute disseminated encephalomyelitis. 29 Jun 2009
• [The relationship between level of injury and bladder behavior in patients with post-traumatic spinal cord injury] 29 Jun 2009
• Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity. 29 Jun 2009
• A systematic evaluation of factors associated with nocturia--the population-based FINNO study. 8 Jun 2009
• Effect of pelvic floor interferential electrostimulation on urodynamic parameters and incontinency of children with myelomeningocele and detrusor overactivity. 22 May 2009
• A UK consensus on the management of the bladder in multiple sclerosis. 29 Apr 2009
• Basic fibroblast growth factor causes urinary bladder overactivity through gap junction generation in the smooth muscle. 20 Apr 2009
• [Impact of disease duration of lumbar disk herniation on bladder dysfunction] 12 Apr 2009
• Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. 28 Mar 2009
• Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg. 17 Mar 2009
• Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. 3 Mar 2009
• Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. 8 Feb 2009
• Effect of antiepileptic agent, levetiracetam, on urodynamic parameters and neurogenic bladder overactivity in chronically paraplegic rats. 21 Jan 2009
• Anticholinergics for urinary symptoms in multiple sclerosis. 19 Jan 2009
• An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats. 30 Dec 2008
• Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction. 30 Dec 2008

See a longer list of these articles.

Technical information about 'Urinary Bladder, Overactive'

Definition: Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.

Descriptor UI: D053201

Alternative terms: Urinary Bladder, Overactive; Overactive Bladder; Overactive Urinary Bladder; Bladder, Overactive; Overactive Detrusor; Detrusor, Overactive; Overactive Detrusor Function; Detrusor Function, Overactive;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C12.777.829.866; C13.351.968.829.813; C23.888.942.775;

History Note: 2007; for OVERACTIVE BLADDER use URINARY INCONTINENCE 2005-2006